Indeed, PAR5 has also been found to be decreased in hepatocellular carcinoma and gliomas [118,119], where, interestingly, PAR5 has been reported to exert a tumor suppressor role through its interaction with EZH2. Here, PWAR5 is linked to central nervous system cancer.